Human cytomegalovirus infection enhances 5‑lipoxygenase and cycloxygenase‑2 expression in colorectal cancer.


Journal

International journal of oncology
ISSN: 1791-2423
Titre abrégé: Int J Oncol
Pays: Greece
ID NLM: 9306042

Informations de publication

Date de publication:
11 2023
Historique:
received: 06 07 2022
accepted: 07 07 2023
medline: 4 9 2023
pubmed: 1 9 2023
entrez: 1 9 2023
Statut: ppublish

Résumé

Colorectal cancer (CRC) is one of the most common and fatal types of cancer. Inflammation promotes CRC development, however, the underlying etiological factors are unknown. Human cytomegalovirus (HCMV), a virus that induces inflammation and other cancer hallmarks, has been detected in several types of malignancy, including CRC. The present study investigated whether HCMV infection was associated with expression of the pro‑inflammatory enzymes 5‑lipoxygenase (5‑LO) and cyclooxygenase‑2 (COX‑2) and other molecular, genetic and clinicopathological CRC features. The present study assessed 146 individual paraffin‑embedded CRC tissue microarray (TMA) cores already characterized for TP53 and KRAS mutations, microsatellite instability (MSI) status, Ki‑67 index and EGFR by immunohistochemistry (IHC). The cores were further analyzed by IHC for the expression of two HCMV proteins (Immediate Early, IE and pp65) and the inflammatory markers 5‑LO and COX‑2. The CRC cell lines Caco‑2 and LS‑174T were infected with HCMV strain VR1814, treated with antiviral drug ganciclovir (GCV) and/or anti‑inflammatory drug celecoxib (CCX) and analyzed by reverse transcription‑quantitative PCR and immunofluorescence for 5‑LO, COX‑2, IE and pp65 transcripts and proteins. HCMV IE and pp65 proteins were detected in ~90% of the CRC cases tested; this was correlated with COX‑2, 5‑LO and KI‑67 expression, but not with EGFR immunostaining, TP53 and KRAS mutations or MSI status.

Identifiants

pubmed: 37654195
doi: 10.3892/ijo.2023.5564
pii: 116
pmc: PMC10546380
doi:
pii:

Substances chimiques

Arachidonate 5-Lipoxygenase EC 1.13.11.34
Cyclooxygenase 2 EC 1.14.99.1
Ki-67 Antigen 0
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2
Celecoxib JCX84Q7J1L
Ganciclovir P9G3CKZ4P5
ErbB Receptors EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Clin Invest. 1997 Dec 15;100(12):3154-63
pubmed: 9399963
J Tissue Eng. 2021 Feb 1;12:2041731420985202
pubmed: 34104387
Tissue Cell. 2011 Jun;43(3):201-6
pubmed: 21470648
Clin Cancer Res. 2020 Aug 1;26(15):4031-4039
pubmed: 32423968
Platelets. 2009 Sep;20(6):386-90
pubmed: 19811222
Am J Gastroenterol. 2006 Jun;101(6):1283-7
pubmed: 16771950
Ann Intern Med. 2013 Jul 16;159(2):77-85
pubmed: 23856681
J Biol Chem. 2002 Feb 8;277(6):4374-9
pubmed: 11706027
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19468-73
pubmed: 19033472
Inflamm Bowel Dis. 2003 May;9(3):154-61
pubmed: 12792220
Inflammation. 2015 Apr;38(2):858-70
pubmed: 25139581
Clin Cancer Res. 2005 Mar 1;11(5):1999-2007
pubmed: 15756026
Ann Oncol. 2006 Jun;17 Suppl 7:vii91-6
pubmed: 16760302
Lancet. 2011 Jan 1;377(9759):31-41
pubmed: 21144578
JAMA Oncol. 2021 Mar 01;7(3):428-435
pubmed: 33475710
Cancers (Basel). 2021 Dec 12;13(24):
pubmed: 34944856
JAMA. 2022 Apr 26;327(16):1585-1597
pubmed: 35471507
Pathogens. 2021 Feb 13;10(2):
pubmed: 33668486
Cells. 2022 Feb 18;11(4):
pubmed: 35203374
Biomed Pharmacother. 1999 Aug;53(7):303-8
pubmed: 10472428
Scand J Gastroenterol Suppl. 2000;(232):101-4
pubmed: 11232485
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13585-90
pubmed: 14593199
Herpesviridae. 2010 Dec 23;1(1):8
pubmed: 21429243
Mol Biol Cell. 2007 Nov;18(11):4245-60
pubmed: 17699589
Clin Cancer Res. 2020 Oct 15;26(20):5297-5303
pubmed: 32719000
Clin Exp Metastasis. 2018 Feb;35(1-2):25-35
pubmed: 29322294
Profiles Drug Subst Excip Relat Methodol. 2018;43:1-208
pubmed: 29678260
Microorganisms. 2020 Sep 24;8(10):
pubmed: 32987955
J Med Virol. 2021 Jun;93(6):4023-4027
pubmed: 33174621
Cells. 2020 Mar 04;9(3):
pubmed: 32143413
Int J Mol Sci. 2019 Nov 28;20(23):
pubmed: 31795299
Antimicrob Agents Chemother. 2014;58(2):986-94
pubmed: 24277030
Int J Cancer. 2013 Nov 15;133(10):2351-61
pubmed: 23661597
Curr Colorectal Cancer Rep. 2016;12:27-34
pubmed: 27069437
Biochem Pharmacol. 1984 May 1;33(9):1525-30
pubmed: 6329230
Oncotarget. 2016 Nov 22;7(47):76735-76742
pubmed: 27732934
Lancet. 1978 May 6;1(8071):957-60
pubmed: 76890
J Exp Med. 2008 Jan 21;205(1):19-24
pubmed: 18180307
Int J Mol Sci. 2019 Mar 05;20(5):
pubmed: 30841568
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Virol J. 2017 Feb 20;14(1):34
pubmed: 28219398
Viruses. 2018 Aug 03;10(8):
pubmed: 30081496
J Clin Virol. 2012 Jul;54(3):240-4
pubmed: 22595308
Methods Mol Biol. 2014;1119:165-96
pubmed: 24639224
Curr Cancer Drug Targets. 2006 Nov;6(7):613-22
pubmed: 17100567
J Pathol. 2015 Jan;235(2):288-97
pubmed: 25205255
Curr Opin Virol. 2019 Dec;39:49-59
pubmed: 31525538
Cancer Metastasis Rev. 2017 Jun;36(2):305-329
pubmed: 28752248
Int J Mol Sci. 2020 Apr 09;21(7):
pubmed: 32283655
J Natl Cancer Inst. 2005 Jul 6;97(13):975-80
pubmed: 15998950
FASEB J. 2001 Sep;15(11):2007-9
pubmed: 11511519
Lancet. 2010 Nov 20;376(9754):1741-50
pubmed: 20970847
Cancer Metastasis Rev. 2018 Sep;37(2-3):257-267
pubmed: 29858741
Virus Res. 2009 Dec;146(1-2):89-96
pubmed: 19748535
Cancers (Basel). 2022 Apr 13;14(8):
pubmed: 35454863
Curr Top Med Chem. 2007;7(3):311-40
pubmed: 17305573
Intervirology. 2020;63(1-6):10-16
pubmed: 32772018
Int J Cancer. 2013 Mar 1;132(5):1022-31
pubmed: 22847294
J Clin Invest. 2010 Nov;120(11):3969-78
pubmed: 20978345
Int J Biol Sci. 2007 Jun 13;3(5):328-34
pubmed: 17589567
Int J Oncol. 2017 Nov;51(5):1415-1426
pubmed: 29048611
Neuro Oncol. 2012 Mar;14(3):246-55
pubmed: 22319219
Oncotarget. 2019 Jul 02;10(42):4333-4347
pubmed: 31303966
J Intern Med. 2006 Mar;259(3):219-46
pubmed: 16476101
Int J Mol Sci. 2018 Oct 23;19(11):
pubmed: 30360467
Cancers (Basel). 2021 Oct 09;13(20):
pubmed: 34680198
Curr Top Microbiol Immunol. 2008;325:297-313
pubmed: 18637513
BMC Cancer. 2006 Jan 30;6:27
pubmed: 16445867
Cell Death Differ. 2022 Aug;29(8):1639-1653
pubmed: 35194187
PLoS One. 2012;7(4):e36190
pubmed: 22558377
J Clin Invest. 2011 Oct;121(10):4043-55
pubmed: 21946257
Oncogene. 2018 Jul;37(30):4110-4121
pubmed: 29706656
J Lipid Res. 2009 Apr;50 Suppl:S40-5
pubmed: 18987389
Gastroenterology. 2018 Jun;154(8):2152-2164.e19
pubmed: 29458155
Rev Med Virol. 2019 May;29(3):e2034
pubmed: 30706584
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Transl Oncol. 2014 Dec;7(6):732-40
pubmed: 25500083
J Cell Physiol. 2008 Aug;216(2):543-50
pubmed: 18330889
Placenta. 2014 Jun;35(6):345-50
pubmed: 24746852
Cancers (Basel). 2021 Feb 03;13(4):
pubmed: 33546238
J Natl Cancer Inst. 2009 Feb 18;101(4):256-66
pubmed: 19211452
Cell. 1997 Oct 3;91(1):119-26
pubmed: 9335340
Circ Res. 1998 Jul 27;83(2):210-6
pubmed: 9686761
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13068-73
pubmed: 16924106
Cancer Res. 2009 Apr 1;69(7):2861-9
pubmed: 19318580
Korean J Physiol Pharmacol. 2015 May;19(3):263-8
pubmed: 25954132
Nat Rev Immunol. 2021 Oct;21(10):653-667
pubmed: 33911231
Science. 2012 Nov 23;338(6110):1088-93
pubmed: 23180859
Clin Cancer Res. 2017 Apr 15;23(8):1898-1909
pubmed: 28411277
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cancers (Basel). 2021 Dec 29;14(1):
pubmed: 35008324
J Clin Virol. 2013 May;57(1):36-42
pubmed: 23391370
Clin Microbiol Infect. 2014 Jul;20(7):664-71
pubmed: 24118412
Lancet. 2002 Nov 16;360(9345):1557-63
pubmed: 12443594
Histol Histopathol. 1998 Apr;13(2):591-7
pubmed: 9589912
Cancer Res. 2002 Jun 15;62(12):3347-50
pubmed: 12067971
J Surg Oncol. 2010 Jun 15;101(8):706-12
pubmed: 20512947
J Cancer Res Clin Oncol. 2019 Aug;145(8):2083-2095
pubmed: 31203442
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3932-7
pubmed: 11867761
Curr Colorectal Cancer Rep. 2012 Dec;8(4):316-324
pubmed: 23293573
J Virol. 2011 Dec;85(23):12750-8
pubmed: 21937636
J Urol. 2003 Sep;170(3):998-1002
pubmed: 12913758
Microbes Infect. 2006 Jul;8(8):2236-44
pubmed: 16782382
Curr Top Microbiol Immunol. 2008;325:63-83
pubmed: 18637500
Viruses. 2022 Apr 14;14(4):
pubmed: 35458542
Front Cell Infect Microbiol. 2020 Mar 31;10:130
pubmed: 32296651

Auteurs

Mattia Russel Pantalone (MR)

Department of Medicine, Solna, Microbial Pathogenesis Unit, Karolinska Institutet, 17164 Stockholm, Sweden.

Nerea Martin Almazan (N)

Department of Medicine, Solna, Microbial Pathogenesis Unit, Karolinska Institutet, 17164 Stockholm, Sweden.

Rossano Lattanzio (R)

Center for Advanced Studies and Technology, G. d'Annunzio University, I‑66100 Chieti, Italy.

Chato Taher (C)

Department of Basic Sciences, Hawler Medical University, Erbil 44001, Iraq.

Simone De Fabritiis (S)

Center for Advanced Studies and Technology, G. d'Annunzio University, I‑66100 Chieti, Italy.

Silvia Valentinuzzi (S)

Center for Advanced Studies and Technology, G. d'Annunzio University, I‑66100 Chieti, Italy.

Faraz Bishehsari (F)

Division of Digestive Diseases, Rush Center for Integrated Microbiome and Chronobiology Research, Rush University Medical Center, Chicago, IL 60612, USA.

Mahboobeh Mahdavinia (M)

Digestive Disease Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran 14114, Iran.

Fabio Verginelli (F)

Center for Advanced Studies and Technology, G. d'Annunzio University, I‑66100 Chieti, Italy.

Afsar Rahbar (A)

Department of Medicine, Solna, Microbial Pathogenesis Unit, Karolinska Institutet, 17164 Stockholm, Sweden.

Renato Mariani-Costantini (R)

Center for Advanced Studies and Technology, G. d'Annunzio University, I‑66100 Chieti, Italy.

Cecilia Söderberg-Naucler (C)

Department of Medicine, Solna, Microbial Pathogenesis Unit, Karolinska Institutet, 17164 Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH